Methodology and Delimitation {#s1}
============================

A PubMed database search on 4^th^ April 2018 with the keywords "miRNA AND circulating" resulted in a total of 3558 articles. When the parameter "full-text" was applied, 3510 articles remained. After a second parameter, "free full-text," was applied, a total of 2055 articles were left. These articles were then manually classified into a group of original articles and a group of "others" (not related to the topic, reviews, reports, editorials, commentaries, etc.) Here we are focusing on original articles considering exosomal and non-exosomal circulatory miRNAs as potential biomarkers. A total of 69 original articles were found to be related to the topic.

Among the selected original articles, only six reported on non-exosomal circulating miRNAs: four studied microparticle (MP)-associated miRNAs, and two studied high-density lipoprotein (HDL)-associated miRNAs ([**Figure 1**](#f1){ref-type="fig"}; [**Table 1**](#T1){ref-type="table"}). Meanwhile, a total of 31 of the original articles selected were exosomal miRNA studies: 15 used only plasma, 13 used only serum, 1 used both urine and plasma, 1 used plasma and serum, and 1 used only unstimulated whole saliva as the source of miRNAs for their study ([**Figure 1**](#f1){ref-type="fig"}; [**Table 2**](#T2){ref-type="table"}). On the other hand, 32 of the original articles selected formed a group that were both exosomal and non-exosomal studies: 9 used only plasma, 14 used only serum, 1 used serum and saliva, 1 used vitreous humor and serum, 1 used whole blood and serum,2 used plasma and conditioned media, and 4 used serum and conditioned media as the source of circulating miRNAs ([**Figure 1**](#f1){ref-type="fig"}; [**Tables 3**](#T3){ref-type="table"} and [**4**](#T4){ref-type="table"}).

![Pie chart showing the distribution of 32 selected articles in which a miRNA origin was preferred, according to their comparative study findings. Out of 32 articles, 18 chose exosomes, 1 chose EVs, 1 chose MVs, 3 chose Ago-2 complexes, 1 chose cell-free, 7 chose unfractioned, and 1 showed similar expression between whole serum versus exosomes, as the best origin for miRNAs used in biomarker studies.](fphar-10-01500-g001){#f1}

###### 

Summary of original articles involving non-exosomal circulating miRNAs as biomarkers.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference            Source of miRNAs                                                                           MP/HDL isolation method                                                                                                           miRNA isolation method           miRNA-related experiment                                     Highlighted miRNAs                                                                                                        Potential biomarker                                                                                                Other information
  -------------------- ------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------- -------------------------------- ------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B47]               Endothelial microparticles (EMPs) - platelet-poor plasma                                   Centrifugation at 18,000 g                                                                                                        RNeasy MinElute cleanup kit^f^   RT-qPCR                                                      miR126-3p                                                                                                                 Vascular endothelial repair in different glucose tolerance                                                         Downregulation in hyperglycemic condition resembling vascular protection of miR-126-3p is lost in early phases of glucose intolerance

  [@B176]              EMPs - plasma                                                                              Centrifugation at 13,000 g                                                                                                        NA                               RT-qPCR                                                      miR-92a                                                                                                                   Early detection of acute myocardial infarction (AMI); differentiation from stable coronary artery disease (SCAD)   1\. Upregulation pattern:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               AMI \> SCAD \> control\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               2. miRNA expression parallel with increase in CD31^+^/CD42b^−^ MPs\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               3. AUC of EMPs, miR-92a, and cTnI were 8.925, 8.883, and 9.123, respectively, suggesting combination usage for a more specific and sensitive biomarker

  [@B61]               MP-containing and cell-free plasma                                                         Centrifugation at 13,000 g                                                                                                        TRIzol-based miR isolation       RT-qPCR                                                      miR-126 and miR-26                                                                                                        SCAD                                                                                                               1\. Downregulation of miRNAs in diabetic vs. non-diabetic patients\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               2. Downregulation leads to high risk of coronary artery disease (CAD)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               3. MP plasma miRNAs were better than cell-free miRNAs in predicting cardiovascular events in SCAD patients

  [@B113]              HDL - serum                                                                                Isopycnic density gradient UC                                                                                                     miRNeasy serum/\                 1\. Pathway-focused Human CVD miScript miRNA PCR array^f^\   miR-486 and miR-92                                                                                                        Vulnerable CAD                                                                                                     Upregulation in vulnerable CAD vs. stable CAD
                                                                                                                                                                                                                                                    plasma kit^f^                    2. RT-qPCR                                                                                                                                                                                                                                                                                                

  HDL~2~ - serum       miR-486                                                                                    Upregulation in both unstable vagina (UA) and myocardial infarction (MI) patients; can differentiate between CAD and stable CAD                                                                                                                                                                                                                                                                                                                                              

  HDL~3~ - serum       miR-92                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  [@B27]               MPs - platelet                                                                             Centrifugation at 16,000 g                                                                                                        Trizol                           1\. RT-qPCR\                                                 miR-19, miR-21, miR-132, miR-133, miR-146, miR-155, miR-223, miR-377, miR-451, miR-641, miR-887, miR-1246, and miR-4284   CAD                                                                                                                miRNAs were associated with MP-containing plasma compared to MP-free plasma of CAD patients
                                                                                                                                                                                                                                                                                     2. Next-generation sequencing^c^                                                                                                                                                                                                                                                                          

  [@B144]              HDL - serum                                                                                PEG-6000 method                                                                                                                   Qiazol miRNA-easy kits^f^        RT-qPCR                                                      miR-223                                                                                                                   Weight loss                                                                                                        Downregulation in HP patient vs. normal protein diet

  miR-16 and Mir-122   According to previous study: downregulation in gastric bypass bariatric surgery patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^c^Illumina; ^f^Qiagen.

AMI, acute myocardial infarction; AUC, area under the curve; CAD, coronary artery disease; EMP, endothelial microparticle; HDL, high-density lipoprotein; HP, high protein; hsa, "homo sapiens" = human microRNA prefix; let, microRNA prefix that is conserved in many species; miRNA, microRNA; miR, mature form of microRNA, NA, not available; PEG, polyethylene glycol; RT-qPCR, real-time reverse transcription polymerase chain reaction; SCAD, stable coronary artery disease; UA, unstable vagina; UC, ultracentifugation.

###### 

Summary of original articles involving exosomal miRNAs as biomarkers.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                   Source                                                 Exosome isolation method                               miRNA isolation method                                                  miRNA-related experiment                                                                               Highlighted miRNAs                                                                                                                                                Potential biomarker                                                                                               Other information
  ----------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------ ----------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B43]                                                      Serum                                                  qEV size exclusion\                                    HiPure liquid RNA/\                                                     1\. Small RNA sequencing^c^\                                                                           miR-17-5p and miR-92a-3p                                                                                                                                          Primary vs. metastatic colorectal cancer (CRC)                                                                    Upregulation of miRNAs is associated with pathologic stages and grades of CRC
                                                                                                                     columns^a^                                             miRNA kit^b^                                                            2. Stem-loop RT-qPCR                                                                                                                                                                                                                                                                                                                                                                       

  [@B87]                                                      Plasma                                                 ExoCap exosome isolation and enrichment kit^d^         NA                                                                      RT-qPCR                                                                                                miR-96-5p and miR-149                                                                                                                                             Stage III CRC                                                                                                     

  [@B168]                                                     Serum                                                  Total exosome isolation kit^e^                         Trizol LS of miRNeasy mini kit^f^                                       1\. Microarray^g^\                                                                                     miR-638                                                                                                                                                           CRC                                                                                                               Downregulation of miRNA associated with increase in liver metastasis and later tumor/nodes/metastasis (TNM) stage of CRC
                                                                                                                                                                                                                                                    2. RT-qPCR                                                                                                                                                                                                                                                                                                                                                                                 

  miR-548c-5p, miR-638, miR-5787, miR-8975, and miR-6869-5p   Involved in the process of glucose metabolism in CRC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  [@B116]                                                     Pooled serum; pooled plasma                            Ultracentrifugation (UC)                               miRNeasy mini kit^f^                                                    miRCURY LNA™ universal RT microRNA PCR analysis                                                        miR-16-5p, miR-23a-3p, miR-23b-3p, miR-27a-3p, miR-27b-3p, miR-30b-5p, miR-30c-5p, and miR-222-3p                                                                 CRC                                                                                                               miRNAs were tumor originated

  [@B115]                                                     750 µl serum                                           UC                                                     Trizol-LS reagent + RNeasy mini spin columns^f^                         1\. Microarray^h^\                                                                                     miR-23a                                                                                                                                                           Early-stage CRC                                                                                                   95% sensitivity for stage 1
                                                                                                                                                                                                                                                    2. RT-qPCR                                                                                                                                                                                                                                                                                                                                                                                 

  miR-1246                                                    90% sensitivity for stage 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  [@B163]                                                     Plasma                                                 ExoQuick^i^                                            miRNeasy micro kit^f^                                                   RT-qPCR                                                                                                miR-125a-3p                                                                                                                                                       Colon cancer                                                                                                      1\. Upregulation in patients with early-stage colon cancer\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               2. miRNA AUC = 68.55%; existing marker-CEA AUC = 83.6%;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               combination miR-125a-3p and carcinoembryonic antigen (CEA) AUC = 85.5%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               3. miR-125a-3p = significant correlation with only nerve infiltration (P \< 0.01), but CEA level correlated with tumor size, infiltration depth, and differentiation degree (P \< 0.05, r = 0.3009-0.7270)

  [@B147]                                                     Serum                                                  ExoRNeasy serum/\                                      miRNeasy mini kit^f^                                                    qPCR                                                                                                   mir-193a                                                                                                                                                          Tumor progression of colon cancer                                                                                 Upregulation of miRNA shown in human colon cancer patients with more advanced disease
                                                                                                                     plasma midi kit^f^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  [@B74]                                                      Plasma                                                 PEG system                                             Plasma/\                                                                Real-time PCR                                                                                          let-7i                                                                                                                                                            Multiple sclerosis (MS)                                                                                           Regulates MS pathogenesis by blocking the IGF1R/TGFBR1 pathway
                                                                                                                                                                            Serum Circulating\                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                            and Exosomal RNA Purification kit^j^                                                                                                                                                                                                                                                                                                                                                                                                                               

  [@B32]                                                      1000 µl serum                                          RNase\                                                 Plasma/\                                                                Small RNA sequencing^c^                                                                                miR-15b-5p, miR-23a-3p, miR-30b,-5p, miR-223-3p, miR-342-3p, miR-374-5p, miR-432-5p miR-433-3p, and miR-485-3p                                                    Relapsing-remitting MS vs. progressive MS                                                                         
                                                                                                                     +\                                                     Serum Circulating and Exosomal RNA Purification Mini kit^j^                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                     SEC (Qev^a^)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  [@B127]                                                     Plasma                                                 ExoEasy Maxi and exoRNeasy kit^f^                      ExoRNeasy serum/\                                                       Small RNA sequencing                                                                                   miR-10a-5p, miR-10b-5p, miR-23b-3p, miR-26b-5p, miR-30c-5p, miR-99a-5p, miR-125a-5p, miR-125b-5p, miR-140-3p, miR-186-5p, miR-378a-3p, miR-451a, and miR-342-3p   Cognitive decline in normal aging/presymptomic stage of disease                                                   Monteral Cognitive Assessment (MoCA) scores were negatively correlated with 13 miRNAs, but the miRNA profile was different to previous reported in Alzheimer\'s disease
                                                                                                                                                                            plasma maxi kit^f^                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  [@B125]                                                     100 µl plasma                                          ExoQuick^i^                                            SeraMir RNA isolation kit^i^                                            Ross score                                                                                             miR-129-p                                                                                                                                                         Heart failure (HF) in univentricular heart disease independent of ventricular morphology or stage of palliation   miRNA level is inversely related to the degree of clinical heart failure as assessed by Ross score

  [@B102]                                                     Plasma                                                 UC                                                     mirVana PARIS RNA isolation kit^e^                                      1\. Megaplex miRNA primer pool^k^\                                                                     miR-30d                                                                                                                                                           HF disease management                                                                                             Upregulation of miRNA in coronary sinus (CS) patient with HF
                                                                                                                                                                                                                                                    2. RT-qPCR                                                                                                                                                                                                                                                                                                                                                                                 

  [@B120]                                                     200 µl plasma                                          Total exosome isolation (from plasma) kit^e^/UC        Total exosome RNA and protein isolation kit^e/^MinElute cleanup it^f^   1\. miRNA profiling: Megaplex pools\                                                                   miR-483-5p                                                                                                                                                        Adrenocortical cancer (ACC) vs. adrenocortical adenomas (ACA)\                                                    Upregulation of miRNA in ACC compared to ACA, with AUC 0.965, sensitivity of 87.5%, and specificity 94.45
                                                                                                                                                                                                                                                    2. RT-qPCR                                                                                                                                                                                                                                                               preoperative diagnosis of ACC                                                                                     

  [@B111]                                                     800 µl serum                                           PEG                                                    Trizol LS^l^                                                            RT-qPCR                                                                                                miR-122 and miR-200a                                                                                                                                              Liver disease                                                                                                     Upregulation of miRNAs in anti-retroviral therapies (ART)-treated, HIV-1 infected individuals prior to the development of fatal liver disease

  [@B107]                                                     150 μl plasma                                          ExoQuick^i^                                            QIAzol Lysis + Direct-zol™ RNA MiniPrep isolation kit^m^                1\. Microarray^n^\                                                                                     miR-30a and miR-192                                                                                                                                               Liver disease                                                                                                     1\. Upregulation of miRNAs in alcoholic patients\
                                                                                                                                                                                                                                                    2. RT-qPCR                                                                                                                                                                                                                                                                                                                                                                                 2. miRNA-192 has AUC = 0.95; p \< 0.001

  [@B143]                                                     [Serum:]{.ul}\                                         Filtration through 0.22-mm filter + UC                 miRNeasy mini kit^f^                                                    1\. Microarray (3D-gene human miRNA oligo chips)\                                                      miR-718                                                                                                                                                           Recurrence and therapeutic targets of hepatocellular carcinoma (HCC)                                              Downregulation in patients with tumor recurrence after liver transplant (LT)
                                                              1500 µl (microarray)\                                                                                                                                                                 2. RT-qPCR                                                                                                                                                                                                                                                                                                                                                                                 
                                                              and 300 µl for RT--qPCR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  [@B89]                                                      300 µl plasma                                          ExoQuick^i^                                            NA                                                                      1\. miRNA profiling °\                                                                                 miR-10b-5p, miR-21-5p, and miR-23b-3p                                                                                                                             Non-small-cell lung cancer (NSCLC)                                                                                Upregulation of miRNAs were independently associated with poor survival in NSCLC patients
                                                                                                                                                                                                                                                    2. RT-qPCR                                                                                                                                                                                                                                                                                                                                                                                 

  [@B15]                                                      500 µl plasma                                          ExoQuick^i^                                            Rneasy Lysis Buffer RLT^f^ + Trizol^l^                                  qRT-PCR                                                                                                miR-139-5p,\                                                                                                                                                      [Screening test:]{.ul}\                                                                                           97.5% sensitivity, 72% specificity, and AUC ROC of 90.8%
                                                                                                                                                                                                                                                                                                                                                           miR-200b-5p,\                                                                                                                                                     nodule (lung adeno-carcinomas\                                                                                    
                                                                                                                                                                                                                                                                                                                                                           miR-378a, and\                                                                                                                                                    +carcinoma) vs. non-nodule (healthy former smokers)\                                                              
                                                                                                                                                                                                                                                                                                                                                           miR-379                                                                                                                                                           lung adeno-carcinomas + carcinoma                                                                                 

  miR-30a-3p, miR-100,\                                       [Diagnostic test: Only nodule population]{.ul}\        96% sensitivity, 60% specificity, and AUC ROC of 76%                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  miR-151a-5p, miR-154-3p, and miR-200b-5p                    Lung adenocarcinoma vs. granuloma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  [@B75]                                                      1000 µl unsti-mulated whole saliva                     Total exosome isolation reagent^e^                     Total exosome RNA and protein isolation kits^e^                         1\. PCR array analyses and data analysis: neuropathic and inflammatory miScript miRNAs PCR array^p^\   miR203a-3p                                                                                                                                                        Low oral health-related quality of life (OHRQoL) group vs. high-OHRQoL                                            Upregulation of miRNA in low-OHRQoL
                                                                                                                                                                                                                                                    2. RT-qPCR                                                                                                                                                                                                                                                                                                                                                                                 

  [@B69]                                                      450µl serum                                            ExoQuick^i^                                            Trisure reagent                                                         1\. qPCR\                                                                                              miR-27-3p, miR-28-3p, miR-30a-5p, miR-106-5p, miR-126-5p, and miR-148a-3p                                                                                         Metabolic and inflammatory status as a result of hormonal changes at menopause                                    miRNA levels significantly associated with serum 17β-estradiol
                                                                                                                                                                                                                                                    2. small RNA sequencing^c^\                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                    3. RT-qPCR                                                                                                                                                                                                                                                                                                                                                                                 

  [@B29]                                                      200 µl serum                                           Total exosome isolation reagent (from serum)^e^        Total exosome\                                                          RT-qPCR                                                                                                miR-27b and miR-29                                                                                                                                                Cardio-respiratory fitness                                                                                        Upregulation of miRNAs
                                                                                                                                                                            RNA and protein isolation kit^e^                                                                                                                                                                                                                                                                                                                                                                                                                                   

  [@B16]                                                      500 µl serum                                           ExoQuick^i^                                            miRNeasy mini kit^f^                                                    qPCR                                                                                                   miR-223                                                                                                                                                           Acute ischemic stroke occurrence, stroke severity, and short-term outcomes                                        Upregulation of miRNAs

  [@B173]                                                     plasma                                                 ExoQuick^i^\                                           miRNeasy micro kit^f^                                                   Small RNA sequencing^c^                                                                                miR-125a and miR-1343-3p                                                                                                                                          Colon cancer; prostate cancer including castration-resistant and hormone-sensitive; pancreatic cancer             1\. Down-regulation with all cancer types tested with \<0.05 false rate\
                                                                                                                     +\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        2. AUC 0.68 to 0.92, depends on cancer type and stage
                                                                                                                     RNAse A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  [@B103]                                                     600 μl serum                                           Total exosome isolation reagent for serum^e^           mirVana PARIS kit^e^                                                    RT-qPCR                                                                                                miR-373                                                                                                                                                           More aggressive breast carcinomas                                                                                 Association of levels with triple negative

  [@B52]                                                      Plasma                                                 ExoQuick^i^                                            TRIzol                                                                  1\. Next-generation sequencing^c^\                                                                     miR-21 and\                                                                                                                                                       Breast cancer (accompany another diagnostic tool)                                                                 AUC 0.73 (95% CI 0.53, 0.92; P = 0.022)
                                                                                                                                                                                                                                                    2. RT-qPCR                                                                                             miR-1246                                                                                                                                                                                                                                                                            

  [@B70]                                                      Plasma                                                 Total exosome isolation reagent^e^                     miRNeasy mini kit^f^                                                    Microarrays^h^                                                                                         hsa-miR-483-3p                                                                                                                                                    Intermittent hypoxia (IH) exposure                                                                                Exosomal role as cell-to-cell communicator

  [@B2]                                                       1000 µl serum                                          ExoQuick^i^                                            mirVana PARIS miRNA isolation kit^e^                                    1\. miRNA profiling (scano-miR platform)\                                                              Prostate cancer (Pca) miRNAs:\                                                                                                                                    Very high-risk (VHR) Pcas patients vs. low-risk patients and healthy subjects VHR aggressive Pca                  Differentiate population with at least 89% accuracy
                                                                                                                                                                                                                                                    2. RT-qPCR                                                                                             miR-106a, miR-135a\*, miR-200c, miR-433, and miR-605                                                                                                                                                                                                                                

  [@B55]                                                      250 µl plasma                                          ExoQuick^i^+\                                          miRNeasy micro kit^f^                                                   RT-qPCR                                                                                                miR-375 and miR-1290                                                                                                                                              Castration-resistant prostate cancer (CRPC)                                                                       Upregulation of miRNAs significantly associated with overall survival
                                                                                                                     RNase A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  [@B126]                                                     500 µL plasma                                          Exosome RNA isolation kit^j^                           NA                                                                      1\. Microarrays^g^\                                                                                    miR-30b,\                                                                                                                                                         Minimal change disease (MCD) patients vs.\                                                                        Upregulation of miRNAs
                                                                                                                                                                                                                                                    2. RT-qPCR                                                                                             miR-30c,\                                                                                                                                                         focal glomerulo-sclerosis (FSGS) patients and control subjects                                                    
                                                                                                                                                                                                                                                                                                                                                           miR-34b,\                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                           miR-34c, and miR-342                                                                                                                                                                                                                                                                

  1000 µL urine                                               miR-1225-5p                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  miR-1915 and miR-663                                        FSGS vs. MCD and control subjects                      Downregulation of miRNAs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  miR-155                                                     Upregulation of miRNAs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  [@B58]                                                      250µl plasma                                           ExoQuick^i^                                            TRIzol LS^l^                                                            RT-qPCR                                                                                                miR-155 and\                                                                                                                                                      HIV-1 pathogenesis, disease progression, association with inflammatory state, and\                                miRNA expression strongly correlated with exosome abundance and size in ART-naïve patients
                                                                                                                                                                                                                                                                                                                                                           miR-223                                                                                                                                                           efficacy of anti-retrovirus therapy (ART) treatments                                                              

  [@B169]                                                     250 µL serum                                           UC                                                     TRIzol^q^ + miRN-easy mini kit^f^                                       microarray°                                                                                            hsa-miR-20a-5p,\                                                                                                                                                  T-cell function in nasopharyngeal carcinoma (NPC)                                                                 Upregulation of miRNAs in NPC patients leads to downregulation of the MARK1 signaling pathway and alters cell proliferation and differentiation.
                                                                                                                                                                                                                                                                                                                                                           hsa-miR-24-3p,\                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                           hsa-miR-891a, hsa-miR-106a-5p, and hsa-miR1908                                                                                                                                                                                                                                      
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Izon Science Ltd.; ^b^Magen, China; ^c^Illumina; ^d^JSR Micro Materials Innovations; ^e^Ambion; ^f^Qiagen; ^g^Affymetrix; ^h^Agilent; ^i^System Biosciences; ^j^Norgen; ^k^Applied Biosystems; ^l^Life Technologies; ^m^Zymo Research Corp; ^n^Firefly BioWorks; °Exiqon; ^p^SA biosciences; ^q^Invitrogen.

ACA, adrenocortical adenomas; ACC, adrenocortical cancer; ART, anti-retroviral therapies; AUC, area under the curve; CRC, colorectal cancer; CRPC, castration-resistant prostate cancer; CS, coronary sinus; FSGS, focal segmental glomerulosclerosis; HCC, hepatocellular carcinoma; HF, heart failure; hsa, "homo sapiens" = human microRNA prefix; IH, intermittent hypoxia; let, microRNA prefix that is conserved in many species; LT, liver transplant; OHRQoL, oral health-related quality of life; MCD, minimal change disease; miRNA, microRNA; miR, mature form of microRNA, MoCA, Montreal Cognitive Assessment; MS, multiple sclerosis; NA, not available; NPC, nasopharyngeal carcinoma; NSCLC, non-small cell lung cancer; PEG, polyethylene glycol; PCa, prostate cancer; qPCR, quantitative polymerase chain reaction; ROC, receiver operating curve; RT-qPCR, real-time reverse transcription polymerase chain reaction; UC, ultracentifugation; VHR, very high risk.

###### 

Summary of articles with comparable performance between exosomal, non-exosomal circulating miRNAs, and unfractioned miRNA samples as potential biomarkers.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                   Sources of miRNAs                                                        Exosomal & non-exosomal isolation method   miRNA isolation method                              miRNA-related experiment                                                        Highlighted miRNAs                                                                                                                                                                                                                  Better miRNA source according to findings                                                         Potential biomarker
  --------------------------- ------------------------------------------------------------------------ ------------------------------------------ --------------------------------------------------- ------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- -----------------------------------------------------------
  [@B156]                     Tumor cells vs. whole plasma vs. EVs plasma                              Size exclusion chromate-graphy (SEC)       Trizol-LS^l^                                        1\. Small RNA sequencing^c^\                                                    miR-24-3p, miR-127-3p, miR-21-5p, miR-155-5p, and let-7a-5p                                                                                                                                                                         EV plasma                                                                                         Hodgkin\'s disease
                                                                                                                                                                                                      2. Multiplex stem-loop RT-PCR                                                                                                                                                                                                                                                                                                                                                                                         

  [@B8]                       (200 µl):\                                                               Exosome RNA isolation kit                  mirVana miRNA isolation kit^e^                      RT-qPCR                                                                         miR-146a                                                                                                                                                                                                                            Exosomal plasma                                                                                   Heart failure (HF)
                              whole plasma vs. exosomal plasma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  [@B21]                      (250 µl):\                                                               Total exosome isolation reagent^l^         Total RNA Isolation kit^j^                          RT-qPCR                                                                         miR-423, miR-199 and miR-93\*                                                                                                                                                                                                       Exosomal serum                                                                                    Acute graft-versus-host disease
                              whole serum vs. exosomal serum                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  [@B24]                      Whole serum\                                                             NA                                         mirVana kit^e^                                      RT-qPCR                                                                         miR-1 and miR-133a                                                                                                                                                                                                                  Whole serum                                                                                       Subclinical diabetic cardio-myopathy
                              validated with cultured cells vs. exosomal conditioned media                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  [@B35]                      (400 µl):\                                                               SEC                                        Modified miRN-easy Micro Kit^f^\                    RT-qPCR                                                                         miR-375                                                                                                                                                                                                                             Whole plasma                                                                                      Prostate cancer (Pca) vs. benign prostatic hyperplasia
                              whole plasma vs. EV plasma                                                                                          5 volumes of QIAzol Lysis                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  miR-200c-3p and miR-21-5p   EV plasma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  [@B86]                      (400 ml):\                                                               ExoQuick^i^                                miRNeasy serum/\                                    RT-qPCR                                                                         miR-141                                                                                                                                                                                                                             Exosomal serum                                                                                    Pca
                              whole serum vs. exosomal serum                                                                                      plasma kit^f^                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  [@B44]                      800 µl whole serum\                                                      NA                                         miRNeasy RNA isolation kits^f^                      1\. Microarray^h^\                                                              miR-17-5p and miR-25-3p                                                                                                                                                                                                             Whole serum:\                                                                                     Osteosarcoma
                              validated using cell culture and exosomal conditioned media                                                                                                             2. RT-qPCR                                                                                                                                                                                                                                                                                                          based on validated cultured studies                                                               

  [@B56]                      Tissues,\                                                                ExoQuick^i^                                mirVana\                                            RT-qPCR                                                                         MiR-20b-5p, miR-28-3p, and miR-192-5p                                                                                                                                                                                               Similar performance; need thorough study using other vesicles and complexes to make comparisons   esophageal squamous cell carcinoma (ESCC)
                              200 µl\                                                                                                             PARIS kit^e^                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                              arterial whole serum, 200 µl exosomal serum                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  [@B71]                      425 µl whole plasma vs. exosomal plasma                                  UC                                         RNeasy MinElute columns^f^                          Small RNA sequencing^c^                                                         miR-12, miR-23a, miR-25, miR-26b, miR-30a, miR-30d, miR-93, miR-140\*, miR-122, miR-144, miR-182, and miR-186                                                                                                                       Whole plasma                                                                                      Relapse lymphoma

  [@B91]                      Whole serum vs. exosomal serum vs. cell-free serum                       ExoQuick^i^                                mirVana™ miRNA isolation kit^e^                     RT-qPCR                                                                         miR-125b                                                                                                                                                                                                                            Exosomal serum                                                                                    Recurrence and survival of hepatocellular carcinoma (HCC)

  [@B40]                      (400 μl):\                                                               NA                                         Trizol reagent^l^                                   1\. Microarray\                                                                 miR-519d, miR-21, and miR-221                                                                                                                                                                                                       Exosomal serum                                                                                    HCC
                              exosomal serum vs. non-exosomal serum                                                                                                                                   2. RT-qPCR                                                                                                                                                                                                                                                                                                                                                                                                            

  [@B140]                     (500 μl):\                                                               ExoQuick^i^                                miRNeasy serum/plasma kit^f^                        RT-qPCR                                                                         miR-18a, miR-101, miR-106b, miR-122, miR-195, miR-221, miR-222, and miR-224                                                                                                                                                         Exosomal serum                                                                                    HCC
                              whole serum vs. exosomal serum                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  [@B106]                     Cells vs. 200 µl exosomal serum                                          NA                                         miRNeasy serum plasma isolation kit^f^              RT-qPCR                                                                         miR-223, miR-760, and miR-145                                                                                                                                                                                                       Exosomal miRNAs showed to be released from cells asso-ciated with upregulation of inflammation    Chronic lumbar radicular pain

  [@B123]                     Tissues vs. exosomal plasma vs. cell-free plasma                         ExoQuick^i^                                TRIzol reagent                                      TaqMan-based miRNA profiling: TaqMan array human miRNA platform                 hsa-miR-19a, hsa-miR-512-3p, hsa-miR-27b, hsa-miR-20a, hsa-miR-28-3p, hsa-miR-200c, hsa-miR-151-3p, hsa-miR-223, hsa-miR-20b, hsa-miR-22, hsa-miR-516-3p, hsa-miR-370, hsa-miR139-5p, hsa-miR-145-3p, hsa-let-7e, and hsa-miR-30c   Exosomal plasma                                                                                   Squamous cell carcinoma

  [@B129]                     3 000 µl: whole blood vs. whole serum vs. exosomal serum                 miRCURY exosome isolation kit°             miRCURY RNA isolation kit-biofluids°                Next-generation sequencing^c^                                                   miR-193a-5p and miR-125-5p                                                                                                                                                                                                          Exosomal serum                                                                                    Septic shock

  [@B153]                     (200 µl):\                                                               SEC                                        MiRNeasy mini kits^f^                               1\. Microarray^h^\                                                              miR-92B-3p                                                                                                                                                                                                                          Exosomal serum                                                                                    Synovial sarcoma (SS)
                              exosomal serum vs. Ago2 complexes                                                                                                                                       2. RT-qPCR                                                                                                                                                                                                                                                                                                                                                                                                            

  [@B171]                     200 µL\                                                                  NA                                         QIAzol and the miRNeasy mini kit^f^                 1\. Small RNA sequencing^c^\                                                    miR-142-3p, miR-26a-5p, miR-374a-5p, miR-766-3p, miR-200a-3p, miR-328-3p, miR-130b-3p, and let-7d-5p                                                                                                                                Circulating miRNAs in whole serum were believed to be exosomal-originated                         Ovarian cancer
                              (RT-qPCR)/\                                                                                                                                                             2. RT-qPCR                                                                                                                                                                                                                                                                                                                                                                                                            
                              600 µL\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                              (NGS): whole serum\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                              validated in exosomal conditioned media vs. cultured cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  [@B28]                      (200 μl): whole plasma\                                                  NA                                         Exiqon miRCURY biofluids total RNA isolation kits   1\. miRNA profiling°\                                                           miR-29a-3p, miR-150-5p                                                                                                                                                                                                              Whole plasma                                                                                      Thoracic radiation therapy for non-small cell lung cancer
                              validated with cultured cells vs. exosomal conditioned media                                                                                                            2. RT-qPCR                                                                                                                                                                                                                                                                                                                                                                                                            

  [@B34]                      (100 μl):\                                                               Exo-spin\                                  miRNeasy kit^f^                                     microRNA analyses                                                               Cardiac expressed miRs: miR-1, miR-24, miR-133a/b, miR-208a/b, and miR-210\                                                                                                                                                         Exosomal plasma                                                                                   Myocardial damage
                              whole plasma vs. exosomal plasma                                         mini-columns^r^                                                                                                                                                                Non-vascular miR-122                                                                                                                                                                                                                                                                                                                  

  [@B154]                     (250 μl):\                                                               ExoQuick^i^                                miRNeasy\                                           RT-qPCR                                                                         miR-21, miR-29a, and miR-92a                                                                                                                                                                                                        Whole serum                                                                                       Large adenomatous polyps
                              whole serum vs. exosomal serum                                                                                      kit^f^                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  [@B122]                     (200 µl):\                                                               NA                                         miRNeasy serum/plasma kit^f^                        1\. Global profiling\                                                           miR-122                                                                                                                                                                                                                             Ago2-free serum                                                                                   Non-alcoholic fatty liver disease (NAFLD)
                              whole serum vs. Ago2 complexes serum vs. cell-free and Ago2-free serum                                                                                                  2. In-situ hybridization (ISH)\                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                      3. RT-PCR\                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                      4. Cell culture and transfection                                                                                                                                                                                                                                                                                                                                                                                      

  [@B124]                     Vitreous humor (VH) vs. exosomal VH vs.\                                 UC                                         miRNeasy mini kit^f^                                miRNA profiling (TaqMan low density array)                                      miR146a                                                                                                                                                                                                                             Similar expression                                                                                Uveal melanoma (UM)
                              (400 µL):\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                              whole serum vs. exosomal serum                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  [@B33]                      (400 μL):\                                                               ExoQuick^i^                                mirVana PARIS kit^e^                                1\. qRT-PCR\                                                                    miR-101 and miR-373                                                                                                                                                                                                                 Exosomal serum                                                                                    Aggressive breast carcinomas
                              whole serum vs. exosomal serum vs. cell-free serum                                                                                                                      2. Luciferase assay^s^                                                                                                                                                                                                                                                                                                                                                                                                

  [@B60]                      (250 µl):\                                                               Centrifugation at 13,000 g                 TRIzol LS^l^                                        RT-qPCR                                                                         miR-126 and miR-199a                                                                                                                                                                                                                MV plasma                                                                                         Cardiovascular events in stable coronary artery patients
                              MVs plasma vs. cell-free plasma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  [@B81]                      (250 µl):\                                                               ExoQuick^i^                                modified miRNeasy kit^f^                            1\. Mega-plex profiling\                                                        miR-744, miR-130a, miR-34, let-7d, and let-7e                                                                                                                                                                                       Whole serum                                                                                       Multiple myeloma and monoclonal gammapathy
                              whole serum vs. exosomal serum vs. cell-free serum                                                                                                                      2.qPCR                                                                                                                                                                                                                                                                                                                                                                                                                

  [@B18]                      (250 µl):\                                                               ExoQuick^i^                                TRI reagent                                         RT-qPCR                                                                         miR-17-92                                                                                                                                                                                                                           Exosomal plasma                                                                                   Kaposi\'s sarcoma (KS)
                              exosomal plasma vs. Ago2 complexes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  [@B23]                      (400 µl):\                                                               UC/\                                       mirVana miRNA isolation kit^e^                      RT-qPCR: stem-loop RT-qPCR and Exiqon locked nucleic acid (LNA)-based RT-qPCR   miR-150                                                                                                                                                                                                                             Exosomal serum                                                                                    Immunization
                              whole serum vs. exosomal serum                                           ExoMir filters                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^c^Illumina; ^e^Ambion; ^f^Qiagen; ^h^Agilent; ^i^System Biosciences; ^l^Life Technologies; °Exiqon; ^r^Cell guidance system; ^s^Promega.

ESCC, esophageal squamous cell carcinoma; EV, extracellular vesicle; HCC, hepatocellular carcinoma; hsa, "homo sapiens" = human microRNA prefix; KS, Kaposi\'s sarcoma; LNA, locked nucleic acid; let, microRNA prefix that is conserved in many species; miRNA, microRNA; miR, mature form of microRNA, NA, not available; NAFLD, non-alcoholic fatty-lipid disease; PCa, prostate cancer; RT-qPCR, real-time reverse transcription polymerase chain reaction; SEC, size-exclusion chromatography; SS, Synovial sarcoma; UC, ultracentifugation; UM, uveal meloma; VH, vitreous humor.

###### 

Summary of articles using different sources of miRNAs in discussing subjects other than potential biomarkers of a particular disease.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                         Sources of miRNAs                                     Exosomal & non-exosomal isolation method   miRNA isolation method                miRNA-related experiment   Highlighted miRNAs                                                                     Better miRNA source according to findings   Potential biomarker
  ----------------------------------------------------------------- ----------------------------------------------------- ------------------------------------------ ------------------------------------- -------------------------- -------------------------------------------------------------------------------------- ------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B76]                                                            (200 µL):\                                            UC                                         miRNeasy mini Kit^f^                  RT-qPCR                    miR-1, miR-16, miR-21, miR-122 and miR-142-3p                                          Exosomal serum                              1\. Exosomal miRNAs are more stable than cell-free miRNAs\
                                                                    exosomal serum vs. cell-free serum                                                                                                                                                                                                                                                                   2. RNase inhibitor can be used to differentiate between exosomal and cell-free miRNAs faster and more easily than UC

  [@B45]                                                            Whole serum vs. exosomal serum vs. cell-free serum    UC                                         Trizol^q^                             RT-qPCR                    let-7a; miR-92a, miR-142-3p, miR-101, miR-16, miR-107, miR-122, miR-547, and miR-768   Exosomal serum                              Majority of miRNAs in serum and saliva are concentrated in exosomes

  Whole saliva vs. exosomal saliva vs. cell-free saliva             miR-22, miR-202, miR-203, and miR-1273d               Exosomal saliva                                                                                                                                                                                                                                

  [@B85]                                                            Exosomal plasma vs. Ago2 complexes                    Differential centrifugation\               Trizol^q^/\                           RT-qPCR                    miR-16                                                                                 Ago2 complexes                              1\. Vesicle structures such as exosomes provide general protection to vesicle-encapsulated miRNAs.\
                                                                                                                          and\                                       miRNeasy mini kit^f^                                                                                                                                                                                2. Ago2 complexes selectively associated with miRNAs in vesicles under functional status and protect the vesicle miRNAs from degradation by RNases or proteases.
                                                                                                                          UC                                                                                                                                                                                                                                             

  Exosomal conditioned media vs. Ago2 complexes conditioned media                                                                                                                                                                                                                                                                                                        

  [@B6]                                                             Exosomal plasma vs.\                                  UC/SEC                                     miRNeasy kit^f^                       RT-qPCR                    miR-16, miR-92a, and let-7a                                                            Ago2 complexes plasma                       Two populations of circulating miRNAs exist in plasma: Ago2 complexed and vesicles (exosomes)-bound; suggested that circulating Ago2 complexes are a mechanism responsible for the stability of plasma miRNAs
                                                                    Ago2 complexes plasma                                                                                                                                                                                                                                                                                

  [@B152]                                                           (400 µl): exosomal plasma vs. Ago2 complexes plasma   UC                                         Tri-Reagent LS^t^ + miRNeasy kit^f^   qRT-PCR                    hsa-miR-16, has-miR-21, and has-miR-24                                                 Ago2 complexes plasma                       Majority of nuclease-resistance extracellular miRNA in plasma and cell culture media is floating outside exosomes and is bound to Ago2 protein

  Exosomal conditioned media vs. Ago2 complexes conditioned media   Ago2 complexes conditioned media                                                                                                                                                                                                                                                                     
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^f^Qiagen; ^q^Invitrogen; ^t^Sigma.

Ago, Argonoute; hsa, "homo sapiens" = human microRNA prefix; let, microRNA prefix that is conserved in many species; miRNA, microRNA; miR, mature form of microRNA, NA, not available; RT-qPCR, real-time reverse transcription polymerase chain reaction; SEC, size-exclusion chromatography; UC, ultracentifugation.

Biomarker {#s2}
=========

A biomarker is defined as an objectively measured and evaluated indicator of normal biological processes, pathogenic processes, or pharmacological responses to therapeutic intervention. A biomarker can thus provide impartial information regarding the current physiological state of living organisms ([@B49]). Biomarkers exist in the form of antibodies ([@B22]: IgG-ZEBRA as a biomarker in young patients with nasopharyngeal carcinoma), microbes ([@B137]: the fecal microbiome as a biomarker of colorectal cancer), DNA ([@B148]: sequencing of circulating cell-free DNA \[cfDNA\] from human blood plasma as a noninvasive methodology to study age-associated changes in the epigenome *in vivo*), RNA/miRNA (as tabulated in this review), lipids ([@B136]: the lipid fraction of the solid non-enhancing region showed potential as a novel prognostic biomarker of survival outcome in glioma), metabolites \[[@B92]: a urinary metabolite of polycyclic aromatic hydrocarbons, 8-hydroxy-2′-deoxyguanosine (8-OHdG), can be a biomarker of oxidative stress in pregnant women\], and/or protein \[[@B167]: serum protein, the insulin-like growth factor-binding protein 1 (IGFBP-1), as a biomarker for the early detection of gastrointestinal cancer\]. Alteration in biomarker concentration, structure, function, or action can be associated with the onset, progression, or even regression of a particular disorder as a result of how the body responds to it ([@B49]).

A biomarker needs to pass several tests before it can be successfully used clinically. These tests are (1) preclinical testing, performed using patient samples and confirmed at the *in vitro* and *in vivo* levels, (2) feasibility analysis, which involves the usage of small patient subpopulations to demonstrate the ability to discriminate diseased from healthy subjects, (3) the validation process, which is used to confirm that the biomarker has been assayed properly, and (4) statistical analysis, which is carried out to evaluate the discriminatory accuracy of the biomarker in a large patient population ([@B49]).

MicroRNA (miRNA) {#s3}
================

Origin {#s3_1}
------

miRNAs can originate from intergenic or intragenic (both exonic and intronic) genomic regions, transcribed into long primary transcripts called pri-miR, which are folded back and form double-stranded hairpin structures. The pri-miR will be subjected to a sequential process to produce miRNAs. First is the production of precursor molecules called pre-miR (80-120 nucleotides) in the nucleus by type III endonuclease DROSHA. These pre-miRs are then exported to the cytoplasm, mediated by EXPORTINS, and are later processed by another type of endonuclease, DICER, into short "active" molecules called miRNAs ([@B128]). These mature miRNAs will then be integrated into the RNA-induced silencing complex (RISC) to exhibit their role as gene expression regulators ([@B105]; [@B114]).

Source of Circulating miRNAs {#s3_2}
----------------------------

Circulating miRNAs, which are found in body fluids such as in saliva, serum, plasma, and milk, can be secreted or produced as a result of various events, such as (1) passive leakage from cells that suffer injury, chronic inflammation, apoptosis, or necrosis, or perhaps from cells with a short half-life like platelets, (2) active secretion *via* cell-derived membrane vesicles such as microparticles (MPs), exosomes, shedding vesicles, and apoptotic bodies, and (3) active secretion by a protein-miRNA complex, whereby miRNAs build an association with either or both of lipoproteins (e.g., high-density lipoprotein: HDL) and Argonaute protein (e.g., Ago2) ([@B128]).

Factors Contributing to the Stability of Circulating miRNAs and Its Benefits to Biomarker Development {#s3_3}
-----------------------------------------------------------------------------------------------------

Circulating miRNAs are unusually stable due to (1) their packaging in vesicles, such as in exosomes ([@B18]) or apoptotic bodies, (2) their RNA folding and size, and/or (3) their presence in Ago-containing ribonucleic acid: protein (RNP) complexes ([@B18]), with nucleophosmin ([@B81]), or with high-density lipoproteins (HDL) ([@B76]; [@B40]). The stability of miRNAs results from their resistance toward the action of ribonucleases ([@B60]; [@B28]; [@B8]; [@B89]; [@B171]; [@B23]; [@B85]). This stability means that they are long-lived in biological fluids ([@B124]; [@B34]) and are therefore proposed as attractive diagnostic ([@B122]) and prognostic biomarkers ([@B40]). Their easy accessibility through the collection of body fluids such as blood derivatives, saliva, or urine also points toward their being an ideal source for miRNA biomarkers ([@B45]). Several experimental studies have also reported resistance of endogenous circulating miRNAs toward severe stressing conditions, such as high temperatures, repeated freeze-thaw cycles ([@B40]), very low or high pH levels ([@B31]), boiling, and extended storage time ([@B154]; [@B29]; [@B43]), which are positive traits for circulating miRNAs as potential biomarkers.

Non-invasive or minimally invasive collection of circulating miRNAs ([@B31]; [@B122]; [@B124]; [@B28]; [@B154]; [@B120]) enables (1) the prevention of repetitive invasive procedures such as tissue biopsy (e.g., liver biopsy in detecting hepatocellular carcinoma (HCC) ([@B140]), dangerous kidney biopsy in distinguishing minimal change disease (MCD) from focal segmental glomerulosclerosis (FSGS) ([@B126]), or bone marrow procedures ([@B81]), (2) the avoidance of possible difficulties in obtaining real samples from cirrhotic patients with liver nodules of uncertain malignancy that are identified *via* imaging techniques ([@B40]), and (3) the avoidance of sampling limitations such lesions being too small to be biopsied and studied using conventional methods ([@B126]).

The availability and easy accessibility of circulating miRNAs enables them to be substitutes for existing tedious and expensive procedures that require a high degree of expertise such as X-ray, computed tomography (CT), positron emission tomography (PET)-CT, magnetic resonance imaging (MRI) ([@B44]), sigmoidoscopy, colonoscopy ([@B154]), ophthalmoscopy, ultrasonography, fundus fluorescein angiography, and indocyanine green angiography ([@B124]). In addition to this, they may fill the gaps where useful biomarkers are yet to be found, with higher specificity and sensitivity (if possible). In cases like FSGS and MCD, miRNA expression has been reported to be able to differentiate diseases that seem similar at first glance or are related to each other yet need different treatment for recovery, to avoid resistance buildup, and to avoid progression into end-stage disease or, at worst, mortality. miRNAs are also able to act as (1) a real-time monitor of drug response, (2) an early detector of recurrence or metastasis, and (3) a substitute for a known serum-based tumor marker of osteosarcoma (alkaline phosphatase \[ALP\]) that sometimes leads to false-positive results (since ALP is generally elevated in children and affected by organ damage) in detecting and monitoring the tumor burden of osteosarcoma ([@B44]). Circulating miRNAs are also reported to be better markers than existing markers, for example, (1) cancer antigen-125 (CA-125) measurement and ultrasonography in detecting ovarian cancer (OvCa) ([@B171]) or (2) squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) ([@B56]).

Limitations in miRNA Biomarker Studies {#s3_4}
--------------------------------------

Nevertheless, although studies on the development of miRNAs as biomarkers are blooming, several limitations should be addressed. One of the main limitations is poor consensus between different studies on a particular disease. This may be due to a lack of standardization in the choice of control population, source of circulating miRNAs (serum/plasma/urine/saliva/etc), isolation protocol ([@B147]; [@B163]), choice of internal and exogenous control ([@B40]; [@B116]; [@B173]; [@B71]; [@B123]), analytical approach (e.g., using microarray versus RT-qPCR), or sample size ([@B113]). The source of miRNAs being the cause of variation in results can be seen in a study reported by [@B56]; tissues versus circulating miRNAs) and a study by [@B129]; cellular versus vesicle or cell-free miRNAs). The second limitation is lacking a large sample size and validation of results in different independent cohorts ([@B45]; [@B107]; [@B28]; [@B61]; [@B8]; [@B56]; [@B71]; [@B89]; [@B123]; [@B171]). The sample size in biomarker studies is usually only suitable for a pilot study. The third limitation is a lack of detailed study of a particular disease. Limitations in financing, facilities, and sample sources can lead to an inability to perform all related experiments on a particular disease in order to reach a conclusive result. Hence, there is still a huge amount of room for uncertainty over whether the published results ([@B61]) show the reality of the disease condition. The fourth limitation is the effect of external factors such as age, gender, the matched control, and other external factors (tobacco, alcohol, etc.); these are usually neglected, but they may contribute to variation in results ([@B123]). [@B127] reported such a case, where hsa-let-7e-5p and hsa-miR-103a-3p expression were decreased while the expression of other miRNAs was elevated in either the blood or plasma of Alzheimer\'s patients. This situation emphasizes the importance of considering age when investigating biomarkers for a disease ([@B127]). The fifth limitation is an inability to specifically pinpoint the origin of the miRNAs. Most of the studies considering circulating miRNAs as biomarkers focused on using blood as the miRNA source. However, human blood contains a variety of cell types, hence making it challenging to identify the cell origin of the particular miRNA focused on in a study ([@B35]; [@B111]).

Extracellular Vesicles (EVs) {#s4}
============================

Extracellular vesicles (EVs), which are produced by cells, can be divided into three main types according to their size and biogenesis: exosomes, microvesicles (MVs), and apoptotic bodies (refer to [**Table 5**](#T5){ref-type="table"} for distinctions between exosomes and other EVs). Previous studies have shown that EVs can be secreted by a variety of cell types and can be isolated from different sources such as blood, urine, breast milk, and saliva. EVs contain different types of molecules, such as DNA, RNA, miRNA, lipids, and proteins. EV membranes are known to protect their contents, for example, from degradation activities by nucleases and proteases and also from micro-environment changes (such as fluctuations in pH and osmolarity). EV contents can be transported from the origin parental cells to a specific recipient cell, either *via* horizontal transfer or *via* distant tissues. The easy accessibility of EVs for isolation, their stability, and the ability of their contents to be transported from cell to cell make EVs attractive sources for diagnostic and prognostic biomarkers ([@B73]).

###### 

Distinctions between exosomes, microvesicles (MVs)/microparticles (MPs), and apoptotic bodies.

  Extracellular Vesicles (EVs)                                                                                                                                                                      
  ------------------------------- ------------------------------------------------------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------
  **Visual**                      ![](fphar-10-01500-g003.jpg)                                                                            ![](fphar-10-01500-g004.jpg)                              ![](fphar-10-01500-g005.jpg)
  **Size (µm)**                   0.03 - 0.1                                                                                              0.1 - 1.0                                                 1.0 - 5.0
  **Markers**                     CD9, CD63, CD81, Alix, TSG101                                                                           Annexin V, integrin, selectin, flotillin-2, CD40 ligand   Annexin V, DNA, histones
  **Biogenesis**                  MVB fusion with parental cell plasma membrane                                                           Parental cell membrane blebbing                           Apoptosis of parental cell
  **Mechanism of release**        Exocytosis of MVBs                                                                                      Budding of parental plasma membrane                       Parental cell shrinkage, followed by blebbing of plasma membrane
  **Detection method**            FACS with CD68 capture, electron microscopy, Western blot                                               FACS and electron microscopy                              FACS and electron microscopy
  **Standard isolation method**   Ultracentrifugation (≥100,000 g), immunoprecipitation (ExoQuick), Size exclusion chromatography (SEC)   Centrifugation 10,000-20,000 g                            No known standard method
  **References**                  [@B96]; [@B73]; [@B153]; [@B17]                                                                         [@B62]; [@B73]; [@B47]; [@B17]                            [@B73]; [@B17]; [@B54]

Based on the current state of knowledge, there are four potential modes for loading miRNAs into extracellular vesicles (EVs), especially in exosomes, although the underlying mechanisms remain largely unclear ([**Figure 2**](#f2){ref-type="fig"}). The first potential mode is *via* ceramide pathways ([@B78]; [@B158]; [@B114]), which are also known as neutral sphingomyelinase 2 (nSMase2)-dependent pathways ([@B79]; [@B175]). Sphingolipid ceramide is known to facilitate the process from endosomal vesicle formation to the transportation of miRNAs into exosomes. This ceramide is produced by hydrolysis of sphingomyelin using neutral sphingomyelinases such as nSMase2. Quantitative studies on exosomal miRNAs have shown that the quantity of exosomal miRNAs is directly proportional to the quantity of nSMase2. As such, nSMase2 inhibition by GW4869 resulted in a reduction of exosomes and exosomal-miRNA export. Conversely, an increase in nSMase2 has been shown to increase the number of exosomal miRNAs ([@B150]; [@B78]; [@B158]; [@B79]). The second potential mode is *via* a specific miRNA motif and the sumoylated heterogeneous nuclear ribonucleoprotein (hnRNP)-dependent pathway ([@B160]; [@B175]; [@B73]). A study by Villarroya et al. showed two important things that can control the loading of miRNAs into exosomes, namely the short sequence motifs in miRNAs (EXOmotifs) and sumoylation of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1). EXOmotifs help hnRNPA2B1 to recognize and bind to specific miRNAs, while sumoylation controls the rate of this binding. Hence, the mutagenesis of EXOmotifs and changes in sumoylated hnRNPA2B1 expression level can affect the loading rate of miRNAs into exosomes. This finding is supported by previous studies that showed the ability of short sequences to guide the transport of RNAs to different subcellular compartments; for example, (1) 20-nucleotide stem-loop sequence was able to direct nuclear-encoded mRNA into mitochondria ([@B161]), and (2) the hexanucleotide terminal motif of miR-29b was able to direct nuclear enrichment of this miRNA ([@B59]; [@B160]). The third potential mode is *via* the 3\'-end miRNA sequence-dependent pathway ([@B77]; [@B175]). Koppers-Lalic et al. performed a comparison between the 3\' end of miRNAs in exosomes and the 3\' end of miRNAs in parental cells (B cells). The profiles from RNA sequencing (RNA-seq) showed that 3\'-end adenylated miRNAs dominated the parental cells, whereas 3\'-end uridylated isoforms dominated the exosomes. A validation study using urine samples confirmed the findings. This suggests that the 3\'-end miRNA sequence might play a role in sorting miRNAs into exosomes ([@B77]). The last potential mode is *via* the miRNA-induced silencing complex (miRISC)-related pathway ([@B48]; [@B41]; [@B175] and [@B84]). Mature miRNA can interact with assembly proteins to form a complex called miRISC. miRISC consists of miRNA, miRNA-repressible mRNA, GW182, and AGO2 (Argonaute-2 protein: miRNA effector protein). Any changes in one of the miRISC components may affect the loading of miRNAs into EVs. For example, a crystal structure study on a eukaryotic AGO human protein, AGO2, showed the presence of a middle (MID) domain in the protein. This domain was shown to mediate interaction preferably with adenine (A) and uracil (U) at the phosphorylated 5\'-end miRNAs. Thus, these miRNAs will probably be found be to enriched in EVs compared to in miRNAs without U or A at their 5\' end ([@B41]). Other findings supporting the role of miRISC in miRNA sorting into exosomes: (1) the main component of miRISC, GW182, was found to be co-localized in multivesicular bodies (MVBs) and exosomes ([@B48]), (2) blockage of the turnover of MVBs into lysosomes (due to loss of Hermansky-Pudlák Syndrome 4 \[HPS4\]) could lead to over-accumulation of miRISC and blockage of MVB formation (due to loss of endosomal sorting complex required for transport \[ESCRT\]), resulting in loss of miRISCs ([@B84]), and (3) changes in miRNA-repressible target levels caused by cell activation, which leads to sorting of miRNAs into exosomes.

![Current state of knowledge on how miRNAs are loaded into exosomes and other extracellular vesicles (EVs). The proposed mechanisms are *via* (i) ceramide pathways, (ii) recognition of EXOmotifs and the sumoylated heterogenous nuclear ribonucleoproteins (hnRNPs)-dependent pathway, (iii) uridylated 3\'end isoforms, or (iv) the miRNA-induced silencing complex (miRISC)-related pathway. Ago2, Argonaute-2; Ex, Exosome; EXOmotif, short sequence motifs in miRNAs; EXP5, exportin-5; hnRNPA2B1, heterogenous nuclear ribonucleoprotein A2B1; ILV, intraluminal vesicle; miRISC, miRNA induced silencing complex; nSMase2, neutral sphingomyelinase 2.](fphar-10-01500-g002){#f2}

Description of Exosomes {#s4_1}
-----------------------

Exosomes were first discovered by Pan and Johnstone in 1983 during their sheep reticulocyte-related experiment. They termed them 'a type of small vesicles\' responsible for the transportation of receptors into extracellular space during the maturation of sheep reticulocytes ([@B118]). Later, Johnstone et al. described these small vesicles visually, using transmission microscopy, and defined the vesicles as exosomes ([@B67]). Exosomes are the smallest vesicles in the EV group, with diameters starting from 0.03 µm and ranging up to 0.1 µm ([@B17]) or 0.12 µm ([@B39]). The presence of exosomes in a particular source can be confirmed by either: (i) observation of a cup-shaped morphology under negative-staining transmission microscopy or (ii) the presence of exosome markers such as CD63, CD9, and CD81 ([@B138]; [@B96]; [@B51]). Exosomes contain various types of molecules, such as lipids, proteins, lipid rafts, mRNAs, miRNAs, and other non-coding RNAs, such as long non-coding RNAs (lncRNAs) ([@B175]). Various cell types can release exosomes, such as reticulocytes ([@B118]; [@B26]), dendritic cells ([@B109]; [@B57]), B cells ([@B9]), mast cells ([@B166]), T cells ([@B164]), epithelial cells ([@B93]), and tumor cells ([@B99]).

Exosomes are small intraluminal vesicles derived from the exocytosis of multivesicular bodies (MVBs) with plasma membrane ([@B78]; [@B73]). Specifically, the biogenesis of exosomes starts with the internalization of parental cell membrane to produce endosomes. Small vesicles are formed inside endosomes by invaginating parts of the endosome membranes. These endosomes with small vesicles inside them are called multivesicular bodies (MVBs). MVBs or late endosomes later fuse with parental cell membrane to release the intraluminal endosomal vesicles into the extracellular environment to become exosomes ([@B175]). Several molecules have been reported to play crucial roles in the release of exosomes. For example, knockdown of molecules such as Rab27a, Rab27b, or their effectors, SYTL4 and EXPN5, has been shown to result in inhibition of exosome secretion ([@B117]). Meanwhile, molecules such as tumor repressor protein p53 and its downstream effector, TSAP6, can enhance exosome production ([@B172]). In addition, the syndecan-syntenin molecule was shown to support the intraluminal budding of endosomal membranes (a crucial step in exosome development) by directly interacting with the ALIX protein ([@B7]).

Using exosomes as the source for biomarker development might have several advantages when compared to other existing strategies. The exosome contents reflect the status of parental cells ([@B107]; [@B122]; [@B140]; [@B154]; [@B89]; [@B163]; [@B168]). Exosomes are also specific (in terms of type and concentration) ([@B16]; [@B32]; [@B120]), which means that they can reflect an individual\'s health status ([@B15]). This specificity enables the analysis of low-abundance molecules of interest in a less complex environment ([@B107]; [@B125]). Exosomes act as a cargo, transferring their biologically active components ([@B89]) into targeted cells, playing the role of a cell-to-cell communicator ([@B122]; [@B28]; [@B34]; [@B154]; [@B165]; [@B125]; [@B43]).

According to the idea that exosomal miRNAs are the best source compared to non-exosomal, cell-free, or whole unfractionated samples, we summarize the selected studies that focus on biomarker findings where the sole source is exosomes in [**Table 2**](#T2){ref-type="table"}.

Description of Other EVs {#s4_2}
------------------------

### Microvesicles (MVs)/ Microparticles (MPs) {#s4_2_1}

Apart from exosomes, the other type of EVs that is recorded by this review analysis as a potential source for circulating miRNAs is microvesicles (MVs)/microparticles (MPs). MVs/MPs range in size from 0.1 to 1 µm in diameter ([@B17]). These vesicles contain a fraction of the plasma membrane of the parental cells from which the vesicles budded ([@B73]). Specifically, MVs/MPs are produced *via* direct outward blebbing of parental cell plasma membranes, releasing nascent vesicles into the extracellular environment. Following the blebbing of membrane, distinct and localized changes will occur in the protein and lipid components of the plasma membrane, leading to changes in membrane curvature and rigidity. Proteins that are identified to have functional roles in MV/MP biogenesis are: aminophospholipid translocases (flippasae and floppases) ([@B142]), ADP-ribosylation factor 1 (ARF1: activation of contractile machinery *via* myosin light chain kinase \[MLCK\]) ([@B134]), ARF6 (regulates the selective recruitment of proteins into MVs/MPs and activates contractile machinery *via* MLCK) ([@B110]), arrestin domain containing 1 (ARRDC1), Tumor susceptibility gene 101 (TSG101) ([@B112]), diaphanous related formin 3 (DIAPH3) ([@B72]), glutaminase ([@B85]), Hyaluranon synthase ([@B130]), localized protein enrichment ([@B141]), myosin-1a ([@B100]), Rab22a (selective recruitment of proteins to MVs/MPs under hypoxic conditions ([@B162]), and RhoA (links ARF6 activation to MLS phophorylation *via* the ROCK signaling pathway and is involved in actin cytoskeleton rearrangements *via* the RhoA-cofin pathway; [@B85]; [@B134]; [@B135]). Changes in the above components are complemented by a vertical redistribution of MV/MP cargo components, which are selectively enriched within MVs/MPs ([@B151]).

MVs/MPs can be found in blood circulation ([@B83]; [@B47]) as well as other body fluids, such as urine ([@B139]), as a result of the activation of cell membrane and/or apoptosis processes ([@B63]). MVs/MPs can be shed form various types of cells, such as leukocytes ([@B121]), erythrocytes ([@B174]), platelets ([@B27]; [@B97]), or endothelial cells ([@B47]; [@B176]). The shed MVs/MPs may or may not contain receptors of their parental cells ([@B98]; [@B108]). MVs/MPs are known to participate in biological activities associated with inflammation, immune responses, and thrombosis ([@B50]). The intracellular communication of MVs/MPs with targeted cells can be either *via* (1) direct interaction with ligands presented on the surface of targeted cells, (ii) binding of MVs/MPs to the membrane of targeted cells (requires a specific surface antigen), (iii) indirect interaction through modulation of the extracellular environment, or (iv) internalization-fusion to influence gene regulation ([@B25]; [@B50]; [@B94]; [@B98]).

MVs/MPs can be isolated by centrifugation within the range of 13,000 ([@B176]) to 20,000 ([@B61]) g-force, which can be done without a need for specialized ultracentrifugation machinery. Although this factor seems advantageous toward MVs/MPs as compared to exosomes, the literature shows the opposite, with more studies focusing exosomes than on MVs/MPs. Perhaps, the availability of extensive information regarding exosomes contributes to this phenomenon. Only four studies selected in this review ([@B27]; [@B61]; [@B47]; [@B176]) focused solely on MVs/MPs ([**Table 2**](#T2){ref-type="table"}).

### Apoptotic Bodies {#s4_2_2}

Apoptotic bodies are the largest vesicles in the EV group, with a diameter range of 1 to 5 µm ([@B17]). In contrast to exosomes or MVs/MPs, apoptotic bodies are formed only during programmed cell death. The biogenesis of apoptotic bodies starts from apoptosis. A cell that undergoes apoptosis will first experience nuclear chromatin condensation, followed by membrane blebbing and, lastly, the disintegration of cellular components into distinct membranes enclosing vesicles in the apoptotic bodies. Usually, the apoptotic bodies produced will be phagocytosed by macrophages and cleared locally. This clearance process is mediated by interactions between recognition receptors (Annexin V) present on phagocytes with components of the membrane of the apoptotic bodies \[phosphatidylserine translocates to the outer leaflet of the lipid bilayer for the interaction ([@B95])\]. On the other hand, oxidation of surface molecules of apoptotic bodies creates sites for binding of thrombospondin ([@B133]; [@B42]) or the complement protein C3b ([@B145]). This thrombospondin or C3b can then be recognized by phagocyte receptors ([@B36]; [@B104]). Hence, Annexin V, thrombospondin, and C3b are used as markers for apoptotic body studies ([@B132]; [@B1]).

Non-Exosomal: Sources Other Than EVs (HDL-Complexes and Ago2-Complexes) {#s5}
=======================================================================

According to the analysis carried out for this review, the source of non-exosomal miRNAs can be either microvesicles (MVs)/microparticles (MPs), as described in the Extracellular Vesicles (EVs) section or from a protein-miRNA complex (such as high-density lipoprotein \[HDL\] or Argonaute protein \[Ago2\]) ([@B128]). In this section, the HDL and Ago2 sources are described.

In general, very few articles report miRNA biomarker studies using solely a non-exosomal source. Only six such articles were successfully retrieved *via* our search strategy, four of which used only microparticles (MPs) miRNAs and two of which used HDL- miRNAs complexes. We summarize the findings in [**Table 1**](#T1){ref-type="table"}.

High-Density Lipoprotein (HDL) {#s5_1}
------------------------------

High-density lipoprotein (HDL) consists of proteins (75-80%) and lipids (20-25%). The lipids can be fractionated further into phospholipids (65%), triglycerides (30%), and cholesterol (5%). As a major part of HDL is protein, the density of HDL is close to that of protein, which is 1.120 gram per milliliter ([@B19]). The molecular weight of HDL is about 400 kDa, and its diameter ranges from 7 to 20 nm ([@B12]). HDL is formed by a dimer of two monomers, weighing 200 kDa each. Each of the HDL monomers is composed of about five main apoproteins, with molecular weights ranging from 35 to 110 kDa. Each monomer has a funnel-shaped cavity (with a volume of 68 nm^3^), built by 2 beta-sheets (constituted by hydrophobic acids) ([@B4]). Each cavity is large enough to fix about 35 molecules of phospholipids concentrated on a monolayer that interact with the cavity\'s hydrophobic nucleic acid. This hydrophobic cavity protects molecules trapped inside it; as such, phospholipase C can only liberate 6% of the lipid phosphorus of HDLs ([@B13]; [@B5]).

HDL formation is known to taken place in the liver and intestine. The approved biogenesis of HDL involves the interaction of lipid-poor ApoA-1 and ATP binding cassette A1 (ABCA1). ABCA1 is part of the membrane transporter group, functioning as a promoter of transportation of phospholipid and cholesterol from parental cells to poorly lipidated ApoI. The binding of ApoI to ABCA1 has been shown to increase the stability and activity of the transporter in the parental plasma membrane. ATP hydrolysis leads ABCA1 to promote trans-bilayer transportation of phospholipids from the inner to the outer leaflet of the parental plasma membrane. This packing forms extravesiculated lipid domains. ApoI binds to this domain and promotes spontaneous solubilization, which leads to the formation of pre-beta-HDL particles ([@B14]; [@B30]; [@B157]). Other proteins and enzymes that are involved in HDL maturation and remodeling include: (i) ATP-binding cassette sub-family G member 1 (ABCG1) (with ABCA1, synergistically mediates cholesterol efflux to HDL) ([@B46]), (ii) scavenger receptor class B type 1 (SRB1) (mediates cholesterol bidirectional flux from cells and HDL, which modulates changes in the composition and structure of HDL particles) ([@B64]; [@B65]), (iii) lecithin-cholesterol acyltransferase (LCAT) (mediates fatty acid transportation to pre-beta-HDL to form cholesteryl ester) ([@B68]; [@B38]), (iv) cholesteryl ester transfer protein (CETP) (an enzyme that helps in the transportation of both cholesteryl ester and trigylcerides between lipoproteins) ([@B146]; [@B37]), (v) phospholipid transfer protein (PLTP) (mediates phospholipid transportation from ApoB-containing lipoproteins to HDL), and both (vi) hepatic lipase (HL) and (vii) endothelial lipase (EL) (participate in HDL metabolism) ([@B20]).

Recently, HDL has been reported to act as a transporter in delivering miRNAs to recipient cells, and miRNAs have been proven to influence the gene expression in the recipient cell. For example, in a study where the most abundant miRNA transported by HDL, miR-223 (up to 10,000 copies per microgram of HDL), was transported to Huh7 cells showed a significant reduction of miR-223 target gene expression ([@B159]). In addition to that, in this review, two studies ([@B113]; [@B144]) involving human samples also shown evidence for miRNA transportation *via* HDL.

Other than miRNAs, HDL is also reported to act as a carrier of fat-soluble vitamins \[such as vitamin E ([@B131]) and vitamin D ([@B155]; [@B3])\], steroids (lipophilic thyroid hormone thyroxine \[T4\]; [@B10]), hormones (estrogen, pregnenolone and dehydroepiandrosterone; [@B149]), and carotenoids (lycopene, lutein; [@B80]; [@B158]).

Argonaute Protein (Ago2) {#s5_2}
------------------------

The term 'Argonaute\' for proteins comes from the findings of the Bohmert group. The group described a mutant protein in *Arabidopsis thaliana* as AGO1 (Argonaute-1) because the leaf morphology of this plant resembles the shape of a small squid named the 'greater Argonaut\' or *Argonauta argo* ([@B11]). Argonaute proteins can be classified into three paralogous groups, which are: (i) Argonaute-like proteins (resembling *Arabidopsis thaliana* AGO1) ([@B11]), (ii) Piwi-like proteins (closely related to *Drosophila melanogaster* PIWI \[P-element induced wimpy testis\]) ([@B88]), and (iii) the *Caenorhabditis elegans-*specific group 3 Argonautes ([@B170]).

There are four domains in an Argonaute protein, namely the N-terminal, PAZ (Piwi-Argonaute-Zwille), Mid (Middle), and PIWI ([@B119]). The N-terminal domain is involved in (i) the loading of small RNAs to the protein, (ii) assisting in the unwinding process of small RNA duplexes ([@B82]), and (ii) together with the PIWI domain, its unstructured loop is plays an important role in the cleavage process ([@B53]). The PAZ domain is responsible for recognizing the 3\'-overhangs of small RNAs and leads the small RNAs into a specific binding pocket inside the protein ([@B66]). The MID domain provides a binding pocket at which the 5\'-terminal bases of small RNAs can form stacking interactions with a conserved tyrosine within it. In addition, several hydrogen bonds help to coordinate correct 5\'-end binding. The PIWI domain is responsible for endonucleases, which cleave target RNA that is fully complementary to the bound small RNA ([@B66]). However, not all Argonaute proteins possess cleavage activity. For example, in mammals, only AGO2 of the AGO subfamily is catalytically active and functioning as an endonuclease ([@B90]; [@B101]).

Apart from being a cleavage location for bound miRNA target genes, Argonaute proteins also play a role as miRNA carriers. This carrier role has been demonstrated in several articles that have been analyzed in this review, for example: (i) Arroyo et al. found that 90% of miRNAs in circulation (from human plasma samples) were present in a non-membrane-bound form consistent with a ribonucleoprotein complex (Ago2 ribonucleoprotein complex) and that this complex provides stability for nonvesicular circulating miRNAs ([@B6]); (ii) the Turchinovich et al. study showed similar results to that of Arroyo et al.; that is, that the majority of nuclease-resistant extracellular miRNAs in both plasma and cell culture media is floating outside exosomes and is bound to the Ago2 protein ([@B152]).

Performance Comparison of Exosomal and Non-Exosomal Circulating mirnas as Potential Biomarkers {#s6}
==============================================================================================

[**Tables 3**](#T3){ref-type="table"} and [**4**](#T4){ref-type="table"} summarize the articles on the role and mechanism of circulating miRNAs and their potential to be used as biomarkers. Out of the total of 69 articles cited, six were exclusively on non-exosomes, 31 were exclusively on exosomes, and the remaining 32 related to both exosomes and non-exosomes. Out of these 32, 18 articles pointed to exosomal miRNAs, six to non-exosomal miRNAs, and 7 to unfractionated samples as a better source for miRNAs used as a biomarker. However, one article differed from the above, stating that similar expression was observed both in whole and exosomal serum samples ([**Figure 1**](#f1){ref-type="fig"}).

Based on the above data, it is obvious that 71% of the articles (31 + 18) concluded that exosomes are the source of choice for miRNAs in biomarker studies. Moreover, taking into consideration the articles (18) that compared both exosomal and non-exosomal miRNAs, 75% recommended an exosomal source of miRNAs over non-exosomal miRNAs. Though the debate on the preference and recommendation of the source of miRNAs, whether exosomal or non-exosomal, is never-ending, summing up the information based on the literature, it can be inferred that the exosomal source of miRNAs can act as a better source for biomarker studies owing to its advantages in terms of quantity, quality, and stability. Hence, the exosomal source of miRNAs holds promise in studies related to biomarkers and diseases, which can be reaped for the benefit of mankind in terms of screening and surveillance. Having said that, the role of other biomarkers for disease diagnosis from other sources cannot be ignored altogether. Further exploration is needed to ascertain how other biomarkers can be used hand-in-hand with miRNAs from exosomal sources; these may complement each other and make disease diagnosis more efficient and timely. This hence warrants further research, exploring other possible resources that can be reaped for early diagnosis, prevention, and treatment of diseases.
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